Cheherazade Trouki

Dr. Cheherazade Trouki

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in The Journal of Physical Chemistry C
Verified
Journal Article
Open access
FMFrancesca Martini
Francesca Martini
LCLucia Calucci
Lucia Calucci
LGLarisa Gordeeva
Larisa Gordeeva
SMSusanna Monti
Susanna Monti
MSMarina V. Solovyeva
Marina V. Solovyeva
SPSilvia Pizzanelli
Silvia Pizzanelli

30 August 2022 in Nanoscale
Verified
Journal Article
Open access
PDF file
CTCheherazade Trouki
Cheherazade Trouki
Giovanni BarcaroGiovanni Barcaro
Giovanni Barcaro
SMSusanna Monti
Susanna Monti
Dynamics of assembling an OLA-functionalized ZnO vehicle, loading an anticancer drug, and releasing the loaded cargo to the target sites.

1 August 2025 in Bioactive Materials
Verified
Journal Article
Open access
CCCaterina Cristallini
Caterina Cristallini
DRDaniela Rossin
Daniela Rossin
RVRoberto Vanni
Roberto Vanni
BNBarbani Nicoletta
Barbani Nicoletta
CBChiara Bulgheresi
Chiara Bulgheresi
Claudia GiachinoClaudia Giachino
Claudia Giachino
We produced a microstructured, electroconductive and nano-functionalized drug eluting cardiac patch (MENDEP) designed to attract endogenous precursor cells, favor their differentiation and counteract adverse ventricular remodeling in situ. MENDEP showed mechanical anisotropy and biaxial strength comparable to porcine myocardium, reduced impedance, controlled biodegradability, molecular recognition ability and controlled drug release activity. In vitro, cytocompatibility and cardioinductivity were demonstrated. Migration tests showed the chemoattractive capacity of the patches and conductivity assays showed unaltered cell-cell interactions and cell beating synchronicity. MENDEP was then epicardially implanted in a rat model of ischemia/reperfusion (I/R). Histological, immunofluorescence and biomarker analysis indicated that implantation did not cause damage to the healthy myocardium. After I/R, MENDEP recruited precursor cells into the damaged myocardium and triggered their differentiation towards the vascular lineage. Under the patch, the myocardial tissue appeared well preserved and cardiac gap junctions were correctly distributed at the level of the intercalated discs. The fibrotic area measured in the I/R group was partially reduced in the patch group. Overall, these results demonstrate that MENDEP was fully retained on the epicardial surface of the left ventricle over 4-week implantation period, underwent progressive vascularization, did not perturb the healthy myocardium and showed great potential in repairing the infarcted area.

8 June 2023 in Journal of Materials Chemistry B
Verified
Journal Article
Open access
PDF file
CTCheherazade Trouki
Cheherazade Trouki
SMSusanna Monti
Susanna Monti
Giovanni BarcaroGiovanni Barcaro
Giovanni Barcaro
Action and dynamics of an anti-cancer drug: how are they affected by an inorganic nanocarrier?

23 August 2023 in Nanoscale
Verified
Journal Article
Closed access
PDF file
SMSusanna Monti
Susanna Monti
CTCheherazade Trouki
Cheherazade Trouki
GBGiovanni Barcaro
Giovanni Barcaro
A look inside the MOF shape-changing tunnels: diffusion trajectory of a guest CO2 molecule.

17 December 2024 in Molecules
Verified
Journal Article
Open access
PDF file
AVAndrea Vornoli
Andrea Vornoli
ASAymen SOUID
Aymen SOUID
BLBarbara Lazzari
Barbara Lazzari
Federica TurriFederica Turri
Federica Turri
FPFlavia Pizzi
Flavia Pizzi
Luisa PozzoLuisa Pozzo
Luisa Pozzo
Beer and its components show potential for reducing hepatic steatosis in rodent models through multiple mechanisms. This study aimed to evaluate beer’s anti-steatotic effects in a high-fat diet (HFD)-induced mouse model of Metabolic dysfunction-Associated Liver Disease (MASLD) and to explore the underlying mechanisms. In the HFD group, steatosis was confirmed by altered blood parameters, weight gain, elevated liver lipid content, and histological changes. These markers were normalized in the HFD+beer group, reaching levels similar to the control (CTR) group. Protein carbonylation and lipid peroxidation levels were consistent across all groups, suggesting that the model represents an early stage of MASLD without oxidative stress. Transcriptomic and CpG methylation analyses revealed clear distinctions between the CTR and HFD groups. RNA sequencing identified 162 differentially expressed genes (DEGs) between the CTR and HFD groups, primarily related to inflammation and lipid regulation. Beer consumption modified the health of the HFD mice, affecting inflammation but not lipid homeostasis (CTR vs. HFD+beer, DEGs = 43). The CpG methylation analysis indicated that beer lowered methylation, impacting genes linked to lipid accumulation and inflammation. A cecal metabolite analysis suggested that beer improved short-chain fatty acid metabolism (SCFA). In summary, a moderate beer intake may mitigate MASLD by modulating lipid metabolism and SCFA pathways, likely through polyphenol activity.